Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multiple-Ascending Dose Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Properties of iN1011-N17 After Oral Administration in Healthy Volunteers and Post-Herpetic Neuralgia Patients and to Assess the Relative Bioavailability of Mesylate vs Hydrochloride Salt Capsules in Healthy Volunteers
NCT06218784 is registered in ClinicalTrials.gov with iN Therapeutics Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled, Multiple-Ascending Dose Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Properties of iN1011-N17 After Oral Administration in Healthy Volunteers and Post-Herpetic Neuralgia Patients and to Assess the Relative Bioavailability of Mesylate vs Hydrochloride Salt Capsules in Healthy Volunteers
- Lead sponsor
- iN Therapeutics Co., Ltd.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- November 11, 2022
- Completion date
- July 29, 2024
- Enrollment
- 64 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
chronic pain, dorsal root ganglion, nav 1.7, neuropathic pain, osteoarthritis, pain, post herpetic neuralgia